Pfizer (PFE) Stock Declines While Market Improves: Some Information for Investors
In the closing of the recent trading day, Pfizer (PFE) stood at $28.61, denoting a -0.21% change from the preceding trading day.
Billionaire Ken Griffin Loaded Up on This High-Yield Dividend Stock. Should You?
A 5.8% forward-dividend yield is just one reason the hedge fund manager likes this stock.
Healthy Returns: Pfizer pulls sickle cell disease drug from markets – here's why it matters
Pfizer withdrew its sickle cell disease treatment Oxbryta. Meanwhile, Senators introduce new bill to fortify health-care cybersecurity following major attacks.
3 Consistent Dividend Stocks for Passive Income: KO, PFE, MO
Everybody loves dividends, essentially investors' form of payday. And these companies have been paying shareholders consistently for years.
Pfizer offloads $3.3 bln stake in Sensodyne-maker Haleon
Pfizer offloaded shares worth roughly $3.26 billion in Haleon at 380 pence apiece, cutting its stake to 15% in the world's largest standalone consumer healthcare firm, a bookrunner said on Tuesday.
Pfizer: Growth From Oncology Franchise; Initiate With 'Buy'
Pfizer's acquisition of Seagen for $43 billion enhances its ADC technology, potentially expanding its oncology franchise and driving future growth. PFE's development of the oral GLP-1 receptor agon...
FDA alerts patients about Pfizer's Oxbryta withdrawal
The U.S. Food and Drug Administration on Thursday alerted patients and healthcare professionals about the withdrawal of Pfizer's sickle cell disease treatment Oxbryta.
Pfizer Withdraws Sickle Cell Disease Therapy Oxbryta From Market
PFE's decision is based on clinical data, which suggests that the overall benefit of the drug no longer outweighs the risk in the approved patient population.
EU regulator recommends suspension of Pfizer's sickle cell disease treatment
The European Medicines Agency (EMA) recommended suspending the marketing authorization for Pfizer's sickle cell disease drug Oxbryta on Thursday.
2 High-Yield Dividend Stocks That Can Deliver a Lifetime of Passive Income
Verizon and Pfizer offer attractive dividend yields above 5%, supported by strong market positions. Both companies face challenges but have strategies in place to maintain their generous payouts.
3 Ultra-High-Yield Dividend Stocks to Buy Now and Hold at Least a Decade
W.P. Carey reduced its dividend after spinning off its office properties last year but still offers an ultra-high yield. Pfizer's been raising its dividend every year since 2009, and an unprecedent...
Pfizer v Moderna COVID vaccine patents battle to go to appeal in UK
Pfizer and Moderna's legal battle over their rival COVID-19 vaccines will continue after London's High Court on Wednesday gave Pfizer permission to take the case to the Court of Appeal.
Pfizer: Oncology Breakthroughs, GLP-1, and Strategic M&A Insights with CFO Dave Denton
In the latest episode of After Earnings, Pfizer CFO Dave Denton shares insights into the company's achievements and future strategies with Ann Berry and Katie Perry. They discuss topics like acquir...
Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron KP.2-adapted COVID-19 Vaccine in the European Union
Upon authorization by the European Commission, the Omicron KP.2-adapted COVID-19 vaccine will be available for individuals 6 months of age and older Data demonstrate that the Omicron KP.2-adapted C...
Pfizer Drug Treating Fatal Weight Loss in Cancer Patients Found Effective
Pfizer (PFE) said this weekend that a drug aimed at helping cancer patients losing appetite and muscle mass showed positive results in a Phase 2 trial.
Related Companies